Management Team

Mr. Chee founded Summer Capital in 2017 and served as its Chairman. Summer Capital is an investment company dedicated to investing in early growth state companies in “new economy” sectors such as fintech, blockchain infrastructure and application, consumption technology and healthcare. He has also served as the Vice Chairman of AMINA Bank AG, a company focused on providing a bridge between traditional finance and digital assets while operating as a FINMA-regulated cryptocurrency bank and offering services such as secure custody, crypto trading, staking, lending, asset management and tokenized products to professional investors, corporations, family offices and institutions globally, since April 2020. In addition, Mr. Chee is the founder of Summer Healthcare Fund, L.P. since February 2021 and Summer Everest Ecosystem Fund, L.P. since September 2023. Each are investment companies focused on healthcare and biotechnology and blockchain ecosystem and financial technology, respectively. Prior to these positions, Mr. Chee was Head of Investment Banking and Head of Global Capital Markets, Asia at UBS AG. From 2000 to 2017, Mr. Chee held a number of positions in UBS AG. Mr. Chee has earned a Doctorate degree in applied finance from the University of Geneva, an Executive Master of Business Administration degree Tsinghua University, a Master of Business Administration degree from New York University and a Bachelor’s degree in mechanical engineering from Stevens Institute of Technology.

Mr. Andreeff has served as our President and Chief Executive Officer since June 2021 after having served as our Interim President and Chief Executive Officer from August 2020 until June 2021. He has also served as a member of our Board of Directors since August 2017. Mr. Andreeff is the General Partner and Portfolio Manager at Maple Leaf Partners, LP. Maple Leaf Partners, LP is a hedge fund founded by Mr. Andreeff, where he has been employed since 1996. In 2003, the fund was seeded by Julian Robertson’s Tiger Management and later grew to over $2 billion in assets under management. Mr. Andreeff also serves as a member of the board of directors of privately-held HDL Therapeutics, Inc. and Myocardial Solutions, Ltd. Mr. Andreeff received his Bachelor’s degree in Economics from the University of Texas at Arlington in 1989 and his Master’s degree in Economics from the University of Texas at Arlington in 1991.

Mr. Mathiesen is an accomplished senior executive and director of public and privately held companies with broad experience in the biopharmaceutical, medical device, semiconductor capital equipment, and water filtration markets. Mr. Mathiesen has served as director and audit committee chair of NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a publicly traded medical technology company providing neuromodulation continuous electroencephalogram monitoring and treatment solutions for patients with epilepsy and other nerve-related disorders, since 2017.

Mr. Mathiesen previously served as director and audit committee chair of Panbela Therapeutics, Inc (NASDAQ: PBLA), a publicly traded biopharmaceutical company developing therapies for pancreatic diseases, from 2015 until April 2025, and as vice chair and lead independent director from 2020 until April 2025. He previously served as director and audit committee chair for eNeura, Inc, a privately held medical technology company providing therapy for both acute treatment and prevention of migraine, from 2018 to 2020.

Mr. Mathiesen previously served as the chief financial officer of Gemphire Therapeutics Inc, a publicly held clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic disorders, and as chief financial officer of Sunshine Heart, Inc, a publicly held early-stage medical device company, both of which completed successful initial public offerings and follow-on equity offerings.

Mr. Mathiesen has held executive and financial management positions with private and publicly traded companies dating back to 1987. He began his career at Deloitte & Touche LLP. Mr. Mathiesen received a BS in Accounting from the University of South Dakota and is also a certified public accountant (Inactive).

Dr. Favit-Van Pelt is a rare disease expert and a pioneer in the field of applied theranostics for the development of disease-modifying treatments. As a board-certified neurologist, she holds a PhD in Pharmacology and has more than 20 years of drug development expertise in the pharmaceutical industry and academia. She started her clinical practice activity in 1994 with specialist clinics in Europe where she continues her involvement as a specialist consultant managing patients with movement disorders and rare neuromuscular disorders.

Dr. Favit-Van Pelt is currently serving as chief medical officer at Solana Company. Previously Dr. Favit-Van Pelt served as head of US Medical Strategy for Neurology at Lundbeck and head of Medical Affairs at Luitpold.

In 2013, she founded Synaerion Therapeutics and its affiliate Thera Neuropharma, Inc (2016), 2 privately held biotechnology companies developing a small molecule regenerative therapy and RNAi-based integrated technology platform for amyotrophic lateral sclerosis (ALS) and traumatic brain injury (TBI), where she oversaw all aspects of the companies’ management and strategy as chief executive officer, president ,and chairwoman of the board from 2014 to 2017 and continues to serve as president and chairwoman. In 2009, she founded StratMedica, LLC, a privately held company designed to provide corporate clients with contract senior management support and directed, as principal from 2009 to 2016, clinical development and medical programs for several healthcare companies, including Johnson & Johnson and Teva. She started her pharmaceutical career in 2001 as global clinical development lead at GE Healthcare (formerly Amersham Health), then as director of medical strategy at Bristol-Myers Squibb in 2005 and, in 2007, as senior director and global medical lead at Shire Pharmaceuticals.